105 related articles for article (PubMed ID: 20089114)
1. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.
Pruthi RS; Nielsen M; Heathcote S; Wallen EM; Rathmell WK; Godley P; Whang Y; Fielding J; Schultz H; Grigson G; Smith A; Kim W
BJU Int; 2010 Aug; 106(3):349-54. PubMed ID: 20089114
[TBL] [Abstract][Full Text] [Related]
2. Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates.
Satyal U; Valentine H; Liu D; Slifker M; Lallas CD; Trabulsi EJ; Bukavina L; Szeto L; Hoffman-Censits JH; Mouw KW; Faltas BM; Grivas P; Ibragimova I; Porten SP; Van Allen EM; Geynisman DM; Parker DC; O'Neill JP; Drevik J; Christianson SS; Ginzburg S; Correa AF; Uzzo RG; Ross EA; Zibelman MR; Ghatalia P; Plimack ER; Kutikov A; Abbosh PH
JCO Precis Oncol; 2024 Jun; 8():e2300362. PubMed ID: 38865671
[TBL] [Abstract][Full Text] [Related]
3. Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer.
Jayaratna IS; Navai N; Dinney CP
Transl Androl Urol; 2015 Jun; 4(3):273-82. PubMed ID: 26816830
[TBL] [Abstract][Full Text] [Related]
4. Honing the Hunt: A Comprehensive Review of Cell-free Tumor DNA to Predict Neoadjuvant Therapy Efficacy in Bladder Cancer.
Suartz CV; Martinez LM; Cordeiro MD; Botelho LAA; Gallutti FP; Mota JM; Leite KRM; Toren P; Nahas WC; Ribeiro-Filho LA
Clin Genitourin Cancer; 2024 Jun; 22(3):102087. PubMed ID: 38688207
[TBL] [Abstract][Full Text] [Related]
5. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.
Pili R; Qin R; Flynn PJ; Picus J; Millward M; Ho WM; Pitot H; Tan W; Miles KM; Erlichman C; Vaishampayan U
Clin Genitourin Cancer; 2013 Dec; 11(4):477-83. PubMed ID: 23891158
[TBL] [Abstract][Full Text] [Related]
6. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
Necchi A; Mariani L; Zaffaroni N; Schwartz LH; Giannatempo P; Crippa F; Morosi C; Lanocita R; Sava T; Ortega C; Messina C; Sacco C; Pennati M; Daidone MG; Nicolai N; De Braud F; Gianni AM; Salvioni R
Lancet Oncol; 2012 Aug; 13(8):810-6. PubMed ID: 22819172
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy for advanced urothelial cancer of the bladder: where do we stand?
Zhu Z; Shen Z; Xu C
Anticancer Agents Med Chem; 2012 Nov; 12(9):1081-7. PubMed ID: 22583418
[TBL] [Abstract][Full Text] [Related]
8. Lysine Methyltransferase 9 (KMT9) Is an Actionable Target in Muscle-Invasive Bladder Cancer.
Totonji S; Ramos-Triguero A; Willmann D; Sum M; Urban S; Bauer H; Rieder A; Wang S; Greschik H; Metzger E; Schüle R
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672614
[TBL] [Abstract][Full Text] [Related]
9. Interruption of the long non-coding RNA HOTAIR signaling axis ameliorates chemotherapy-induced cachexia in bladder cancer.
Hu CY; Su BH; Lee YC; Wang CT; Yang ML; Shen WT; Fu JT; Chen SY; Huang WY; Ou CH; Tsai YS; Kuo FC; Shiau AL; Shieh GS; Wu CL
J Biomed Sci; 2022 Dec; 29(1):104. PubMed ID: 36471329
[TBL] [Abstract][Full Text] [Related]
10. Identification of a naturally-occurring canine model for early detection and intervention research in high grade urothelial carcinoma.
Dhawan D; Ramos-Vara JA; Utturkar SM; Ruple A; Tersey SA; Nelson JB; Cooper BR; Heng HG; Ostrander EA; Parker HG; Hahn NM; Adams LG; Fulkerson CM; Childress MO; Bonney PL; Royce C; Fourez LM; Enstrom AW; Ambrosius LA; Knapp DW
Front Oncol; 2022; 12():1011969. PubMed ID: 36439482
[TBL] [Abstract][Full Text] [Related]
11. Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.
Lang H; Béraud C; Cabel L; Fontugne J; Lassalle M; Krucker C; Dufour F; Groeneveld CS; Dixon V; Meng X; Kamoun A; Chapeaublanc E; De Reynies A; Gamé X; Rischmann P; Bieche I; Masliah-Planchon J; Beaurepere R; Allory Y; Lindner V; Misseri Y; Radvanyi F; Lluel P; Bernard-Pierrot I; Massfelder T
Front Oncol; 2022; 12():930731. PubMed ID: 36033544
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory role of proguanil on the growth of bladder cancer via enhancing EGFR degradation and inhibiting its downstream signaling pathway to induce autophagy.
Xiao D; Hu X; Peng M; Deng J; Zhou S; Xu S; Wu J; Yang X
Cell Death Dis; 2022 May; 13(5):499. PubMed ID: 35614042
[TBL] [Abstract][Full Text] [Related]
13. RNA-seq of nine canine prostate cancer cell lines reveals diverse therapeutic target signatures.
Packeiser EM; Taher L; Kong W; Ernst M; Beck J; Hewicker-Trautwein M; Brenig B; Schütz E; Murua Escobar H; Nolte I
Cancer Cell Int; 2022 Feb; 22(1):54. PubMed ID: 35109825
[TBL] [Abstract][Full Text] [Related]
14. Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer.
Chen D; Ye Y; Guo S; Yao K
Front Mol Biosci; 2021; 8():800945. PubMed ID: 35004854
[TBL] [Abstract][Full Text] [Related]
15. Developing Precision Medicine for Bladder Cancer.
Guercio BJ; Iyer G; Rosenberg JE
Hematol Oncol Clin North Am; 2021 Jun; 35(3):633-653. PubMed ID: 33958155
[TBL] [Abstract][Full Text] [Related]
16. Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy.
Mo Q; Li R; Adeegbe DO; Peng G; Chan KS
Commun Biol; 2020 Dec; 3(1):784. PubMed ID: 33335285
[TBL] [Abstract][Full Text] [Related]
17. Mutant Kras as a Biomarker Plays a Favorable Role in FL118-Induced Apoptosis, Reactive Oxygen Species (ROS) Production and Modulation of Survivin, Mcl-1 and XIAP in Human Bladder Cancer.
Santha S; Ling X; Aljahdali IAM; Rasam SS; Wang X; Liao J; Wang J; Fountzilas C; Li Q; Qu J; Li F
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33217967
[TBL] [Abstract][Full Text] [Related]
18. EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer.
Rose M; Maurer A; Wirtz J; Bleilevens A; Waldmann T; Wenz M; Eyll M; Geelvink M; Gereitzig M; Rüchel N; Denecke B; Eltze E; Herrmann E; Toma M; Horst D; Grimm T; Denzinger S; Ecke T; Vögeli TA; Knuechel R; Maurer J; Gaisa NT
Oncogene; 2020 Oct; 39(44):6856-6870. PubMed ID: 32978523
[TBL] [Abstract][Full Text] [Related]
19. Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications.
Minoli M; Kiener M; Thalmann GN; Kruithof-de Julio M; Seiler R
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32784716
[TBL] [Abstract][Full Text] [Related]
20. Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans.
Knapp DW; Dhawan D; Ramos-Vara JA; Ratliff TL; Cresswell GM; Utturkar S; Sommer BC; Fulkerson CM; Hahn NM
Front Oncol; 2019; 9():1493. PubMed ID: 32039002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
